RetinAI US Inc. (RetinAI) and Fundación Ver Salud (FVS) are pleased to jointly announce that LuxIA ®, their co-developed innovative AI algorithm for Diabetic Retinopathy (DR) screening, has ...

Gerhard Koenig, PhD, CEO of Augustine added: “I look forward to working with both Virginie and Andy, whose skills will be invaluable as we advance our lead program into the clinic and further build ...

Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025 New gene expression signature for cancer patients to predict clinical response ...

Positive recommendation based on clinical, real-world and bioequivalence data supporting feasibility and safety of Phesgo’s administration outside of clinical settings, for example at home1-4 Phesgo ...

Mr. Yevgeniy Meshcherekov is a seasoned financial executive and Chartered Professional Accountant, bringing over 20 years of post-designation experience across public practice, private enterprise, and ...

Singapore , April 30, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL), today announced the closing of the acquisition of Bethesda Medical Pte. Ltd., a leading Singapore-based ...

Egham, UK – 30 April 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company developing and delivering medicines for patients in niche populations, today announces the ...

Le Document d’Enregistrement Universel 2024 de GENFIT comprend notamment : Le rapport du conseil d’administration sur le gouvernement d’entreprise, Les rapports des contrôleurs légaux des comptes sur ...

SAN JOSE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative ...

GENFIT’s 2024 Universal Registration Document includes, in particular : The Statutory Auditors’ reports on the annual and consolidated financial statements and related-party agreements, The table ...

This exclusive private label distribution agreement with Smith+Nephew is a significant development for Nuo ,” commented David Jorden, Nuo’s Chief Executive and Financial Officer. “ We could not ...

Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable ...